183 related articles for article (PubMed ID: 38364701)
1. Genomic characteristics and immune landscape of super multiple primary lung cancer.
Yang Z; Zhou B; Guo W; Peng Y; Tian H; Xu J; Wang S; Chen X; Hu B; Liu C; Wang Z; Li C; Gao S; He J
EBioMedicine; 2024 Mar; 101():105019. PubMed ID: 38364701
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
3. Genetic and immune characteristics of multiple primary lung cancers and lung metastases.
Yang R; Li P; Wang D; Wang L; Yin J; Yu B; Li M; Wang S; Wang Y
Thorac Cancer; 2021 Oct; 12(19):2544-2550. PubMed ID: 34510768
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic characteristics of early-stage multiple primary and independent primary lung adenocarcinoma patients.
Li P; Yang R; Wang D; Wang L; Wang S; Liu C; Li J; Li L; Liu C; Tong Y; Wang Y
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e420-e426. PubMed ID: 35098658
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Zhou P; Chen D; Zhu B; Chen W; Xie Q; Wang Y; Tan Q; Yuan B; Zuo X; Huang C; Zhu H; Li G
Front Immunol; 2020; 11():594212. PubMed ID: 33552051
[TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
7. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
[TBL] [Abstract][Full Text] [Related]
8. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
[TBL] [Abstract][Full Text] [Related]
9. Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.
Tian H; Wang Y; Yang Z; Chen P; Xu J; Tian Y; Fan T; Xiao C; Bai G; Li L; Zheng B; Li C; He J
Cancer Gene Ther; 2023 Mar; 30(3):507-520. PubMed ID: 36653483
[TBL] [Abstract][Full Text] [Related]
10. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing analysis reveals transcriptional heterogeneity of multiple primary lung cancer.
Guo W; Zhou B; Bie F; Huai Q; Xue X; Guo L; Tan F; Xue Q; Zhao L; Gao S
Clin Transl Med; 2023 Oct; 13(10):e1453. PubMed ID: 37846760
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
[TBL] [Abstract][Full Text] [Related]
14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
16. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Lin A; Wei T; Meng H; Luo P; Zhang J
Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
[TBL] [Abstract][Full Text] [Related]
17. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
[TBL] [Abstract][Full Text] [Related]
18. Using molecular characteristics to distinguish multiple primary lung cancers and intrapulmonary metastases.
Li Z; Lv H; Zhang F; Zhu Z; Guo Q; Wang M; Huang C; Guo L; Meng F; Tian Z
PeerJ; 2024; 12():e16808. PubMed ID: 38313018
[TBL] [Abstract][Full Text] [Related]
19. Multiple primary lung cancer: A literature review.
Romaszko AM; Doboszyńska A
Adv Clin Exp Med; 2018 May; 27(5):725-730. PubMed ID: 29790681
[TBL] [Abstract][Full Text] [Related]
20. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
